𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer

✍ Scribed by Suhail M. Ali; Walter P. Carney; Francisco J. Esteva; Monica Fornier; Lyndsay Harris; Wolfgang. J. Köstler; Jean-Pierre Lotz; Diana Luftner; Marie-France Pichon; Allan Lipton

Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
175 KB
Volume
113
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Her-2/neu and EGFR tyrosine kinase activ
Her-2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab-based therapy in patients with metastatic breast cancer
✍ Gernot Hudelist; Wolfgang J. Köstler; Klaus Czerwenka; Ernst Kubista; Johannes A 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 372 KB 👁 1 views

## Abstract Her‐2/__neu__ overexpression in human breast cancer leads to an aggressive biological behavior and poor prognosis. Although the anti‐Her‐2/__neu__ antibody trastuzumab (Herceptin®) has become a valuable therapeutic option for patients with Her‐2/__neu__‐overexpressing breast cancer, man

Serum EGFR and serum HER-2/neu are usefu
Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy
✍ Maria Teresa Sandri; Harriet Ann Johansson; Laura Zorzino; Michela Salvatici; Ri 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 127 KB 👁 1 views

## Abstract ## BACKGROUND. Metronomic chemotherapy has been demonstrated to be of value in patients with advanced breast cancer. No reliable markers of response are available. In breast tumor, HER‐2/__neu__ is a prognostic factor, whereas no definite data exist for EGFR. The aim of the study was t

c-erbB-2 (HER-2/neu) protein and drug re
c-erbB-2 (HER-2/neu) protein and drug resistance in breast cancer patients treated with induction chemotherapy
✍ Laura M. Vargas-Roig; Francisco E. Gago; Olga Tello; María T. Martin de Civetta; 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 French ⚖ 71 KB 👁 2 views

Expression of c-erbB-2 protein has been associated with poor prognosis and poor response to chemotherapy in breast cancer patients. In the present prospective study, we have analyzed whether c-erbB-2, p53 and P170 proteins may be determinants of tumor resistance in locally advanced breast cancer pat

Serum epidermal growth factor receptor/H
Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancer
✍ Christopher Souder; Kim Leitzel; Suhail M. Ali; Laurence Demers; Dean B. Evans; 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 205 KB 👁 2 views

## Abstract ## BACKGROUND. Epidermal growth factor receptor (EGFR, HER‐1, and __erbB__1) is overexpressed in primary breast cancer and had been identified as a poor prognostic factor. ## METHODS. Pretreatment serum EGFR levels were quantified by using an enzyme‐linked immunoadsorbent assay in a